Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics

Introduction and hypothesis Urinary tract infections (UTIs) are considered the most common bacterial infections, especially in women. The objective of this study was to evaluate the use of the sublingual bacterial vaccine Uromune® in order to prevent recurrent UTIs (RUTIs). Methods This study was co...

Full description

Saved in:
Bibliographic Details
Published in:International Urogynecology Journal 2013-01, Vol.24 (1), p.127-134
Main Authors: Lorenzo-Gómez, M. F., Padilla-Fernández, B., García-Criado, F. J., Mirón-Canelo, J. A., Gil-Vicente, A., Nieto-Huertos, A., Silva-Abuin, J. M.
Format: Article
Language:English
Subjects:
Analysis of Variance
Antibiotic Prophylaxis
Antibiotics
Bacterial Vaccines - immunology
Cell suspensions
Data processing
Enterococcus faecalis
Escherichia coli
Female
Gynecology
Humans
Klebsiella pneumoniae
Medicine
Medicine & Public Health
Middle Aged
Original
Original Article
Proteus vulgaris
Recurrence
Recurrent infection
Regression Analysis
Retrospective Studies
Risk Factors
Sulfamethoxazole
Treatment Outcome
Trimethoprim
Urinary tract
Urinary Tract Infections - immunology
Urinary Tract Infections - microbiology
Urinary Tract Infections - prevention & control
Urology
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction and hypothesis Urinary tract infections (UTIs) are considered the most common bacterial infections, especially in women. The objective of this study was to evaluate the use of the sublingual bacterial vaccine Uromune® in order to prevent recurrent UTIs (RUTIs). Methods This study was conceived as a multicenter observational study. The clinical history of 319 women who presented at least 2 episodes of UTI in the last 6 months or 3 in 12 months was reviewed. Data related to treatment and clinical evolution were recorded and analyzed. A total of 159 patients received prophylactic treatment with Uromune® for a period of 3 months (group A) and 160 with sulfamethoxazole/trimethoprim 200/40 mg/day for a period of 6 months (group B). Uromune® contained an inactivated bacterial cell suspension of selected strains of Escherichia coli , Klebsiella pneumoniae , Proteus vulgaris , and Enterococcus faecalis . Results Patients in group A experienced a highly significant reduction in the number of infections compared to patients in group B. In the first 3 months, the mean number of infections was 0.36 versus 1.60 ( P  
ISSN:0937-3462
1433-3023
DOI:10.1007/s00192-012-1853-5